Note 6— Equity

Changes in the components of equity were as follows:

	Six Months Ended January 31, 2018
	Attributable to IDT Corporation			Noncontrolling Interests			Total
	(in thousands)
Balance, July 31, 2017	$	145,734		$	8,823		$	154,557
Dividends declared ($0.38 per share)		(9,440	)		—			(9,440	)
Restricted Class B common stock purchased from employees		(61	)		—			(61	)
Transfer of right to receive equity to Howard S. Jonas		—			(40	)		(40	)
Consolidation of Lipomedix Pharmaceuticals Ltd.		—			558			558
Distributions to noncontrolling interests		—			(717	)		(717	)
Stock-based compensation		1,797			—			1,797
Comprehensive income:
Net loss		(576	)		470			(106	)
Other comprehensive loss		(188	)		—			(188	)
Comprehensive income		(764	)		470			(294	)
Balance, January 31, 2018	$	137,266		$	9,094		$	146,360

Dividend Payments

In the six months ended January 31, 2018, the Company paid cash dividends of $0.38 per share on its Class A common stock and Class B common stock, or $9.4 million in total. In the six months ended October 31, 2016, the Company paid cash dividends of $0.38 per share on its Class A common stock and Class B common stock, or $8.8 million in total.

On March 5, 2018, the Company’s Board of Directors declared a dividend of $0.09 per share for the second quarter of fiscal 2018 to holders of the Company’s Class A common stock and Class B common stock. The dividend will be paid on or about March 23, 2018 to stockholders of record as of the close of business on March 19, 2018.

Stock Repurchases

The Company has a stock repurchase program for the repurchase of up to an aggregate of 8.0 million shares of the Company’s Class B common stock. There were no repurchases under the program in the six months ended January 31, 2018 or 2017. At January 31, 2018, 8.0 million shares remained available for repurchase under the stock repurchase program.

In the six months ended January 31, 2018 and 2017, the Company paid $0.1 million and $1.8 million, respectively, to repurchase 5,170 shares and 94,338 shares, respectively, of Class B common stock that were tendered by employees of the Company to satisfy the employees’ tax withholding obligations in connection with the lapsing of restrictions on awards of restricted stock. Such shares were repurchased by the Company based on their fair market value on the trading day immediately prior to the vesting date.

2015 Stock Option and Incentive Plan

On December 14, 2017, the Company’s stockholders approved an amendment to the Company’s 2015 Stock Option and Incentive Plan to increase the number of shares of the Company’s Class B common stock available for the grant of awards thereunder by an additional 0.3 million shares.

In the six months ended January 31, 2017, the Company received proceeds from the exercise of its stock options of $0.8 million. There were no stock option exercises in the six months ended January 31, 2018. In the six months ended January 31, 2017, the Company issued 73,471 shares of its Class B common stock for the stock option exercises.